antibody discovery

Learn how fully human and humanized mAbs differ in generation, immunogenicity, and function—plus ADA risks and engineering options. Explore Biointron’s platforms.

AbDrop™ isolates diverse, high-affinity antibodies rapidly. Biointron shows how this platform transforms discovery with speed, scale, and precision.

AbDrop™ and HUGO-Ab™ accelerate discovery. Biointron demonstrates how these platforms cut timelines by delivering diverse, high-affinity antibodies faster.

Chimeric antibodies marked a milestone in drug development. Biointron reviews their creation and impact as a foundation for today’s therapeutic antibodies.

Discovery on Target 2024 in Boston highlighted drug discovery. Biointron shares event insights advancing antibody therapeutics and translational science.

Heavy and light chain pairing ensures antigen recognition. Biointron explains its importance in antibody structure, function, and therapeutic application.

Single-cell antibody sequencing reveals repertoire diversity. Biointron applies this method to uncover potent candidates for therapeutic antibody programs.

High-throughput single B cell screening is transforming discovery. Biointron demonstrates how advanced platforms accelerate identification of potent antibodies.

Clear intellectual property policies foster biotech growth. Biointron shows how no-royalty models encourage innovation, collaboration, and therapeutic progress.

Transgenic mouse models enable humanized antibody discovery. Biointron explains why they are essential tools for generating next-generation therapeutics.

Microfluidic technology is transforming biotechnology. Biointron shows how microfluidics enhance antibody research with precision, speed, and innovative applications.

Fully human antibodies reduce immunogenicity and improve safety. Biointron highlights their role in future therapies and the promise they hold for patients.

AET Europe 2024 in London spotlighted antibody innovation. Biointron shares event takeaways on discovery, engineering, and development shaping the therapeutic pipeline.

Learn how transgenic animals are transforming antibody discovery by generating fully human antibodies for biomedical research, diagnostics, and drug development.

In March 2024, Cyagen and Biointron officially signed off on their strategic partnership, forging an alliance in antibody drug development. This partnership aims to fully leverage the strengths of Cyagen's HUGO-Ab™ fully humanized mouse antibody discovery platform and Biointron&#